St. Jude Scientists Reveal Role of Non-Coding DNA Variants in Childhood Leukemia

St. Jude Children's Research Hospital scientists have identified specific DNA variants in the non-coding regions of the genome contributing to chemotherapy resistance in acute lymphoblastic leukemia (ALL). The results guided the team to unravel the mechanism behind a previously unknown contributor to therapeutic resistance. The discovery was enabled by combining new technologies to overcome previous limitations in understanding the non-coding genome, which could be adapted to other types of cancer and diseases. The findings were published today in Nature Communications.

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Survival rates are over 94% due to modern therapy. However, those with relapsed or recurrent disease, often due to chemotherapy resistance, have a much poorer 30-40% survival rate.

The researchers studied resistance variants found in the non-coding genome, which makes up 98% of DNA and does not contain genes. Previous attempts to identify resistance mechanisms to chemotherapy focused on DNA that encoded genes. Looking directly at genes is simpler because non-coding DNA can have complex relationships with gene function, but the St. Jude group showed it is possible.

We demonstrated that we now have the tools to find relevant non-coding genetic factors that contribute to chemotherapy resistance. The end goal is to understand the mechanisms of drug resistance so we can develop novel therapeutics and optimize existing chemotherapies based on the individual's unique genetic makeup."

Daniel Savic, PhD, corresponding author, St. Jude Department of Pharmacy and Pharmaceutical Sciences

Sorting Through Non-Coding DNA to Find the Root of Chemotherapy Resistance

"The non-coding 98% of the genome contains instructions," said co-first author Jackson Mobley, PhD, St. Jude Department of Pharmacy and Pharmaceutical Sciences. "If we are making a building, genes encode the iron bars, wires and concrete; non-coding DNA are the blueprints. We found the small changes in the blueprints that impact how well you respond to certain therapies."

The group explored novel non-coding resistance variants by combining state-of-the-art technologies to examine patient samples and clinical data on treatment outcomes. In the past, research focused on a single gene or variant. However, combining high-throughput DNA sequencing methods allowed the St. Jude researchers to perform massively parallel variant screens. Those large screens enabled the testing of over 1,600 variants simultaneously to identify which were functional. That huge increase made the results more comprehensive, leading to the discovery of over 500 functional non-coding DNA variants associated with chemotherapy resistance.

"Our work represents the largest functional investigation of inherited non-coding variants associated with pharmacological traits, especially in ALL," said co-first author Kashi Raj Bhattarai, PhD, St. Jude Department of Pharmacy and Pharmaceutical Sciences. "We verified that identified variants also have a similar effect in cell lines and patient samples."

A Novel Resistance Mechanism

By surveying many non-coding variants at once, the researchers could find the most impactful ones across different subtypes of ALL and connect them to a specific gene using innovative 3D genome mapping technologies. By finding the mechanism behind how variants in the non-coding genome affect target gene activity, they can figure out how it affects cancer's response to treatment.

For example, the top variant from the screen led to the discovery of a new resistance mechanism. The resistance was to the chemotherapy drug vincristine. The researchers examined how DNA containing the functional variant physically looped to its target gene and which transcription factors, proteins that guide gene expression, were involved. The scientists found the variant bound near the gene for EIF3A, which is known to be involved in cell proliferation and survival. When they deleted the DNA containing the variant or reverted the mutation to the original sequence, they could alter the cells' sensitivity to the chemotherapeutic agent vincristine.

The study serves as a proof of principle of how to take non-coding DNA variants and mechanistically connect them to a trait, such as chemotherapy resistance. That has been a long-standing issue holding back genomics research on inherited variants, from cancer to neurological issues.

"In any genome-wide association study, nearly all associated variants reside in the non-coding genome," Savic said. "Therefore, connecting that variation to gene function and then to an actual trait, such as chemotherapy resistance or disease predisposition, is challenging. We showed that we have harnessed tools and technologies to systematically examine the non-coding genome and understand what it's doing. We hope that our findings can be utilized to improve clinical outcomes in ALL patients."

Authors and Funding

The study's other authors are Christopher Manring, Clara D. Bloomfield Center for Leukemia Outcomes Research; Elias Jabbour and Steven Kornblau, University of Texas MD Anderson Cancer Center; Elisabeth Paietta, Albert Einstein College of Medicine; Mark Litzow, Mayo Clinic; Wendy Stock, University of Chicago Medicine; Kelly Barnett, Daniel Ferguson, Baranda Hansen, Jonathan Diedrich, Brennan Bergeron, Satoshi Yoshimura, Wenjian Yang, Kristine Crews, Hiroto Inaba, Sima Jeha, Ching-Hon Pui, Cheng Cheng, Shondra Pruett-Miller, Mary Relling, Jun Yang and William Evans, St. Jude.

The study was supported by grants from the National Cancer Institute (R01CA234490, P30CA021765, U10CA180820, UG1CA232760562 and UG1CA189859), the National Institute of General Medical Studies (P50GM115279) and ALSAC, the fundraising and awareness organization of St. Jude.